Thirty-minutes infusion rate is safe enough for bevacizumab; no need for initial prolong infusion

Basit Öğe Kaydı
dc.contributor.authorYanmaz, Mustafa Teoman
dc.contributor.authorGüner, Şebnem İzmir
dc.contributor.authorSatılmış, Bahar
dc.contributor.authorAkyol, Hüseyin
dc.contributor.authorAydın, Mehmet Akif
dc.date.accessioned2021-05-15T12:40:41Z
dc.date.available2021-05-15T12:40:41Z
dc.date.issued2014
dc.departmentTıp Fakültesi, Tıbbi Biyokimya Anabilim Dalıen_US
dc.descriptionaydin, mehmet akif/0000-0002-3324-1412
dc.description.abstractBevacizumab (Bev) is a vascular endothelial growth factor-A monoclonal antibody that targets tumor angiogenesis. The transfusion rate of Bev is 90 min in the first dose, 60 min in the second and than from the third dose it is 30 min if no hypersensitivity reaction occurs in the first two doses. The purpose of this study determines whether these initial prolonged infusions are really necessary or not. Between 2007 and 2009, we were using the standard schedule for Bev infusions. In July 2009, we reviewed our medical reports, nursing orders and adverse drug reaction forms to identify the Bev used patients and possible hypersensitivity reactions (HSRs). Depending on that information between August 2009 and July 2014, we started to make Bev infusions in 30 min from the first dose of the therapy. In this study, we documented the findings of these 30-min infusion used patients. From August 2009 to July 2014, we treated 145 patients with 1,145 Bev infusions each one in 30 min. Out of 145 patients, 12 of them received only single dosage of Bev infusion treatment. Bev doses were 5 mg/kg for 87 patients, 7.5 mg/kg for 64 patients, 10 mg/kg for four patients and 15 mg/kg for only one patient. No HSRs were reported during these transfusions. Initial prolonged infusion times are unnecessary for Bev. Thirty-minute infusion rates can be used safely for all courses.en_US
dc.identifier.doi10.1007/s12032-014-0276-1
dc.identifier.issn1357-0560
dc.identifier.issn1559-131X
dc.identifier.issue11en_US
dc.identifier.pmid25294426
dc.identifier.scopus2-s2.0-84919949837
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1007/s12032-014-0276-1
dc.identifier.urihttps://hdl.handle.net/20.500.12939/654
dc.identifier.volume31en_US
dc.identifier.wosWOS:000343058600029
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorYanmaz, Mustafa Teoman
dc.language.isoen
dc.publisherHumana Press Incen_US
dc.relation.ispartofMedical Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHypersensitivity Reactionsen_US
dc.subjectBevacizumaben_US
dc.subjectInfusion Timeen_US
dc.titleThirty-minutes infusion rate is safe enough for bevacizumab; no need for initial prolong infusion
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Temel Tıp Bilimleri Bölümü Koleksiyonu